Effects of rosuvastatin on metabolic profile: Versatility of dose-dependent effect

Al-Kuraishy, Hayder M; Al-Gareeb, Ali I

doi:10.4103/japtr.japtr_330_18

Cited by 25 publications

(16 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[19] These phenomena coincide with our results, since all of the enrolled patients were with high BMI. As well, adipose tissue macrophages are shown to produce prolactin in response to hyperglycemia and diabetic-induced inflammation[20] seeing as CRP levels, FBG, and HbA1c were elevated in our patients. CRP levels reflect the inflammatory changes in patients with T2DM as supported by Hwang et al .…”

Section: Discussionmentioning

confidence: 68%

Effects of diabetic pharmacotherapy on prolactin hormone in patients with type 2 diabetes mellitus: Bane or Boon

Rasheed

Al-Kuraishy

Al-Gareeb

et al. 2019

J Adv Pharm Technol Res

Self Cite

View full text Add to dashboard Cite

Prolactin is a polypeptide hormone secreted from the anterior part of the pituitary gland which was implicated as a diabetogenic factor in the pathogenesis of type 2 diabetes mellitus (T2DM). Therefore, the aim of the present study was to evaluate prolactin serum levels in patients with T2DM regarding the effect of diabetic pharmacotherapy. Eighty patients with T2DM compared with 25 male healthy controls were recruited and divided into four groups: Group I – 29 patients with T2DM treated with metformin, Group II – 30 patients with T2DM treated with glyburide, Group III – 21 patients with T2DM treated with glyburide plus metformin, and Group IV – 25 control male healthy patients. Prolactin serum levels were high in patients with T2DM compared with controls (P < 0.01). Prolactin serum levels were higher in glyburide-treated patients compared with metformin-treated patients (P < 0.01). This study concludes that high prolactin levels in patients with T2DM are linked with diabetic complications and regarded as a beneficial phenomena to overcome IR and diabetic complications. Metformin but not glyburide reduced prolactin levels due to the improvement of insulin resistance.

show abstract

Section: Discussionmentioning

confidence: 68%

Effects of diabetic pharmacotherapy on prolactin hormone in patients with type 2 diabetes mellitus: Bane or Boon

Rasheed

Al-Kuraishy

Al-Gareeb

et al. 2019

J Adv Pharm Technol Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…Body mass index (BMI) is equal to the BW in grams over the square of length in cm, BMI = BW (g)/length (cm) 2 . [13]…”

Section: Methodsmentioning

confidence: 99%

Renoprotective effect of irbesartan in a rat model of gentamicin-induced nephrotoxicity: Role of oxidative stress

2019

View full text Add to dashboard Cite

BACKGROUND: The renin–angiotensin system (RAS) is essential in renal physiology; however, disturbance of the RAS is one of the chief pathways involved in renal injury. Dysregulation of RAS may result in both glomerular and tubulointerstitial injuries through direct effects of angiotensin II (Ang II) type 1 receptor. Irbesartan and other Ang II blockers have renoprotective effect through reduction of on renal inflammations. Therefore, the aim of the present study was to demonstrate the renoprotective effect of irbesartan on gentamicin-induced nephrotoxicity in rats concerning the oxidative stress. MATERIALS AND METHODS: Thirty Sprague-Dawley Male rats divided into three groups, Group I (10 rats) treated with distilled water, Group II (10 rats) treated with gentamicin, and Group III (10 rats) treated with gentamicin plus irbesartan for 12 days. Blood urea, serum creatinine, serum malondialdehyde (MDA), superoxide dismutase (SOD), glutathione reductase (GSH), neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecules (KIM-1), and cystatin-c were measured in each group. RESULTS: Irbesartan significantly reduced blood urea, serum creatinine, serum MDA, NGAL, KIM-1, and cystatin-c P < 0.05. Irbesartan significantly increases SOD P < 0.05 without significant effect in elevation of GSH serum levels. CONCLUSION: Irbesartan has renoprotective effect in attenuation of acute nephrotoxicity through modulation of oxidative stress and antioxidant capacity in rats.

show abstract

“…AnxA1 inhibits pro-inflammatory response through suppression of FPRL-1/ALXR signaling pathway. [ 17 ]…”

Section: Discussionmentioning

confidence: 99%

Statin therapy improves serum Annexin A1 levels in patients with acute coronary syndrome: A case-controlled study

Al-Kuraishy

Al-Gareeb

Samy

2021

Int J Crit Illn Inj Sci

Self Cite

View full text Add to dashboard Cite

Background: The objective of the study is to estimate the protective role of statins in patients with acute coronary syndrome (ACS) through modulation of annexin A1 (AnxA1) serum levels. Methods: A total number of 63 patients with ACS were recruited compared with 25 healthy control subjects. The enrolments were divided into – Group (A): Patients with ACS on atorvastatin ( n = 20), Group (B): Patients with ACS on rosuvastatin ( n = 20), Group (C): Patients with ACS but not on statin therapy ( n = 23), and Group (D): Healthy controls ( n = 25). Body mass index and both systolic blood pressure and diastolic blood pressures were measured. Lipid profile, atherogenic index, cardiac risk ratio, cardiovascular risk index, and human AnxA1 level were estimated. Results: AnxA1 serum level was higher in patients with ACS (3.35 ± 0.84) compared with healthy controls (1.71 ± 0.91) and nonstatin using patients (1.47 ± 0.76) ( P = 0.005). Conclusion: AnxA1 serum level is reduced in patients with ACS compared with healthy controls. Patients with ACS on statins therapy showed a higher level of AnxA1 compared with patients with ACS but not on statin therapy.

show abstract

Effects of rosuvastatin on metabolic profile: Versatility of dose-dependent effect

Cited by 25 publications

References 27 publications

Effects of diabetic pharmacotherapy on prolactin hormone in patients with type 2 diabetes mellitus: Bane or Boon

Effects of diabetic pharmacotherapy on prolactin hormone in patients with type 2 diabetes mellitus: Bane or Boon

Renoprotective effect of irbesartan in a rat model of gentamicin-induced nephrotoxicity: Role of oxidative stress

Statin therapy improves serum Annexin A1 levels in patients with acute coronary syndrome: A case-controlled study

Contact Info

Product

Resources

About